

Recap (CRISPR): How Bacteria Defend Against Phages

Defense Strategies

- **Prevent attachment** → change surface proteins.
Block DNA entry → membrane proteins stop injection.
Stop replication → block phage DNA copying.
Restriction-Modification (RM) → enzymes cut foreign DNA, protect own DNA.
Cell suicide → kill itself to stop phage spread.
CRISPR-Cas → adaptive immune system that remembers past phages.
-

CRISPR-Cas Immune System

What is CRISPR-Cas?

- A **genetic memory system** that helps bacteria recognize and destroy specific phages.
CRISPR = repeated DNA sequences with “spacer” DNA from old phage attacks.
Cas proteins = cutters that destroy matching phage DNA.

Steps in CRISPR Immunity

1. **Spacer Acquisition**
Cas1–Cas2 capture a piece of invading phage DNA and store it as a spacer.
2. **crRNA Biogenesis**
The CRISPR region is copied into RNA, then cut into guide RNAs (crRNAs).
3. **Interference**
Cas protein + crRNA find matching phage DNA and cut it.

PAM Sequence

- CRISPR targets phage DNA only if a **PAM** sequence is present.
This prevents CRISPR from cutting the bacterium’s own DNA.

CRISPR Diversity

- Many types exist (Cas9 is only one example).
Some use one protein; others use many.
They cut DNA in different ways.
-

CRISPR in Genetic Disease Research

1. Studying Diseases

- **Monogenic diseases** (one gene): CRISPR can insert/remove mutations to study them.
- **Polygenic diseases** (many genes): CRISPR can edit **multiple genes at once**, helping study complex diseases like diabetes or schizophrenia.

2. Disease Modeling

- **Cell models** – Edit cells in lab to see how mutations affect them.
- **Animal models** – Edit animals (e.g., mice) to mimic human disease.
- **Xenografts** – Transplant human tissue into animals for testing.
- **Chimeras** – Animals containing human cells to study diseases more realistically.

3. Direct Gene Editing for Therapy

- Fix disease-causing mutations (e.g., sickle cell anemia).
Edit a patient's own cells → correct mutation → return cells to patient.
Potential future: edit embryos to prevent diseases (ethical concerns).

4. Challenges

- **Delivery** of CRISPR into the right cells.
- **Off-target effects** – unintended DNA cuts.
- **Ethics** – embryo editing, equity, long-term risks.

Off-Target Effects (Simple)

- CRISPR may accidentally cut similar DNA sequences → unwanted mutations.
Must be minimized for safe therapy.
-

Engineering Plants for Desired Traits

Vocabulary (Simplified)

- **Selective breeding** – choosing the best plants to reproduce.
Mutation – change in DNA.
Mutagenesis – creating random mutations.
Transgenic – plant has DNA from another organism.
GMO – genetically modified plant (may include foreign DNA).
-

Traditional Methods

Selective Breeding

- Humans pick plants with good traits (big fruits, disease resistance).
Works slowly over many generations.

Mutation Breeding

- Use radiation/chemicals to cause random mutations.
Faster but unpredictable.
-

Modern Genetic Methods - Transgenic Plants (GMOs)

- Add genes from other organisms (e.g., Bt toxin gene from bacteria).
Benefits: pest resistance, less pesticide use.

CRISPR Genome Editing

- Makes **precise** DNA changes without adding foreign DNA.
Faster and more targeted than older methods.
-

Advanced CRISPR Applications in Plants

- **Bioremediation** – plants that clean pollutants (e.g., heavy metals).
Better photosynthesis → more carbon capture.
Biofuel production – plants modified to produce more oils/sugars.

- **Bio-materials** – create plants that produce strong fibers or polymers.
- **Personalized nutrition** – crops tailored for specific dietary needs.
- **Climate resilience** – plants resistant to heat, drought, salinity.

Ethical & Environmental Concerns

- **Unintended effects** on ecosystems.
 - **Loss of biodiversity** if only a few edited varieties dominate.
 - **Gene flow** – edited genes spreading to wild plants.
 - **Access/equity** – ensuring small farmers can benefit too.
-

Designing an effective guide RNA (gRNA) for CRISPR requires careful consideration of several factors to ensure high on-target activity and minimal off-target effects. The design process is typically aided by specialized online software tools.

Key Design Principles

- **Target Specificity:** The gRNA sequence should be unique in the genome to prevent off-target mutations. This is assessed by performing a genome-wide search for similar sequences and using off-target scoring algorithms.
- **Presence of a PAM Site:** The target sequence must be immediately adjacent to a Protospacer Adjacent Motif (PAM) sequence. For the commonly used *Streptococcus pyogenes* Cas9 (SpCas9), the PAM sequence is 5'-NGG-3', where N is any nucleotide. The gRNA does not include the PAM sequence itself.
- **On-Target Efficiency:** The guide should be highly likely to cut at the intended site. On-target efficiency is predicted by algorithms that consider the sequence composition and position of nucleotides.
- **GC Content:** An optimal GC content (typically 40-80%) contributes to gRNA stability and efficient binding to the target DNA.
- **Sequence Length:** The standard length for the target-specific portion of the gRNA is 20 nucleotides for SpCas9. Shorter, truncated gRNAs (17-18 nt)

can sometimes reduce off-target effects while maintaining efficiency in some systems.

- **Secondary Structure:** The gRNA should avoid forming complex secondary structures or self-dimerization, as this can interfere with Cas protein binding and function.
- **Chromatin Accessibility:** The target site should be in an accessible region of chromatin (euchromatin) for the Cas protein to bind effectively.

Experimental Goal Considerations

The specific goal of the experiment influences the design strategy:

- **Gene Knockout (NHEJ):** Target a common exon early in the gene's coding sequence to increase the chance of an out-of-frame mutation and a complete loss of protein function.
- **Gene Knock-in or Point Mutation (HDR):** The gRNA cleavage site must be very close (~30 nucleotides) to the desired edit location or the repair template homology arms for efficient homology-directed repair (HDR).
- **CRISPR Activation (CRISPRa) or Interference (CRISPRi):** Guide RNAs are designed to target specific regions upstream or nearby the transcription start site (TSS) to modulate gene expression.

Recommended Workflow

1. **Define the experimental goal** (knockout, knock-in, etc.).
2. **Identify potential gRNA sequences** near the target site that are adjacent to a PAM sequence using online design tools.
3. **Evaluate top candidates** using the on-target and off-target scores provided by the tools. Select guides with high on-target and low off-target scores.
4. **Consider using multiple gRNAs** for a single target to increase efficiency.
5. **Validate the selected gRNAs experimentally** in your specific cell system or organism to confirm efficiency and specificity.

For the most efficient design, it is highly recommended to use current bioinformatics tools such as **Benchling**, **CRISPOR**, **CHOPCHOP**, or the **Broad Institute GPP sgRNA Designer**, as they use sophisticated algorithms and large datasets to score potential gRNAs.

Gene editing techniques, such as CRISPR/Cas9, are used to create precise changes (like knockouts or specific point mutations) in the *ACE2* gene in cell lines and animal models. This allows scientists to:



- **Understand Normal Function:** By deactivating the gene (ACE2 knockout), researchers can study its essential roles in regulating blood pressure, heart function, kidney function, and placental development.
- **Model Diseases:** Editing the gene helps create models for studying conditions associated with ACE2 dysfunction, such as hypertension, heart failure, and diabetic nephropathy.
- **Investigate Genetic Variations:** Researchers can introduce specific single nucleotide polymorphisms (SNPs) found in the human population to understand how these natural variants affect disease susceptibility and severity, including outcomes in COVID-19 patients.

<https://chopchop.cbu.uib.no/>



Target <input type="text" value="ACE2"/> <small>RefSeq/ENSEMBL/gene ID or genomic coordinates.</small>	In <input type="text" value="Homo sapiens (hg38/GRCh38)"/> <small>Add new species.</small>	Using <input type="text" value="CRISPR/Cas9"/> <small>Change default PAM and guide length in Options.</small>	For <input type="text" value="Knock-out"/> <small>Presets can be adjusted in Options.</small>
--	--	---	---

ACE2



https://www.idtdna.com/site/order/designtool/index/CRISPR_PREDESIGN

Search for predesigned gRNA Design custom gRNA **CRISPR-Cas9 gRNA checker**

The interface includes fields for Species (Homo sapiens), Input format (FASTA Sequence), and a sequence input area containing "GCCTCCATCGATATTAGCAAAGG". Buttons for CHECK and CLEAR AND RESET are also present.


Do not enter the NGG/PAM site

The results show a checker analysis for "Sequence1" with the following scores:

Sequence	On-target score	Off-target score
GCCTCCATCGATATTAGCAA	67	79

Comments: Note these comments before continuing
This gRNA is expected to be good.

[+ ADD TO DESIGN SET](#) [CREATE NEW DESIGN](#)



Sequence

ACE2

Enter a species name for ACE2 to search through Ensembl. If no exact matches are found, species will be ignored.

Genome

GRCh38

Create DNA / RNA sequence

This search is made possible thanks to work by [Yates et. al.](#) and [Zerbino et. al.](#)

Gene: ENSG00000130234

Name: ACE2-201 (ENST00000252519)

Species: GRCh38 (homo_sapiens)

Transcript: ACE2-201 (EN...

Ensembl version: 115

We'll import your data from the most recent Ensembl version.

Import as: Genomic sequence cDNA
You're about to import a genomic sequence with transcript-specific annotations.

Location: Chromosome X 15,494,566—15,607,236 (-)

Import in sense orientation

Upstream bases: 0 **Downstream bases**: 0

Project folder*: CRISPR-CAS



Design CRISPR guides: Guide parameters


Design CRISPR guides: Import sequence

Design type: Single guide
Wild-type Cas9, single gRNA (higher efficiency)

Paired guides
Double Cas9 nickase, two gRNAs (lower off-target effects)

Guides for "base editing" (Komor et al., 2016)
C > T (or G > A) substitution, no dsDNA breaks

Genome: GRCh38 (mm10, Mus musculus)	Guide length: 20
Gene: Ace2 (ENSMUSG00000015405)	Genome: GRCh38 (mm10, Mus musculus)
Location: chrX 164,139,332 - 164,188,420 (*)	PAM: NGG (SpCas9, 3' side)
Transcript: Ace2-002 (ENSMUST00000112271, CCDS3)	Show advanced settings
<input type="checkbox"/> Import cDNA only	
Upstream bp: 0	
Downstream bp: 0	
Sequence Name: Ace2 (ENSMUSG00000015405)	Next <input checked="" type="checkbox"/> Save these as my default CRISPR settings Finish



For a typical gene knockout experiment, the best exon to target is generally located within the **first third of the gene's protein-coding sequence (CDS)** and is an **exon that is common to all or most splice variants**.

Why this location is best:


- **Maximizes the chance of a functional knockout:**
 - Targeting the 5' end ensures that any frameshift mutations (insertions or deletions, or indels) caused by the non-homologous end joining (NHEJ) repair pathway will result in a truncated, non-functional protein.
 - An indel early in the gene is likely to introduce a premature stop codon, which can trigger nonsense-mediated decay (NMD) of the mRNA, further ensuring no functional protein is produced.
 - Avoiding the extreme N-terminus (first exon) helps mitigate the potential for the cell to use an alternative start codon downstream, which could result in a partially functional protein.
 - Avoiding the C-terminus ensures that a large portion of the protein is affected, rather than just the final, potentially non-essential, part.
- **Ensures all isoforms are targeted:** Choosing an exon present in all or most transcript variants (isoforms) means that the knockout will be effective across all forms of the protein, leading to a complete loss-of-function phenotype.
- **Minimizes compensatory mechanisms:** Targeting an "asymmetrical" exon (one whose length is not a multiple of 3 base pairs) ensures that even if the cell tries to skip the exon to restore the reading frame, the skipping itself will still cause a frameshift in the remaining sequence, maintaining the knockout effect.




Other key design considerations:

- **On-target activity and off-target effects:** Beyond location, the specific 20-nucleotide gRNA sequence must be optimized for high on-target efficiency and minimal off-target binding elsewhere in the genome.


Bioinformatics tools (like Benchling, CHOPCHOP, or Synthego's design tool) should be used for this analysis.

- **Chromatin accessibility:** The target region should be in an accessible region of the chromatin (euchromatin) for the Cas9 protein complex to bind efficiently.
- **GC content:** Aim for a GC content of 40-60% for stable gRNA-DNA binding.
- **Multiple gRNAs:** Designing and testing multiple gRNAs for a single gene (e.g., 2 or 3) is recommended to increase the success rate of achieving a complete knockout.





Check if this is hitting the intronic or exon region. **Routine Knockout:** Researchers typically use **2 to 4 high-quality gRNAs per gene** to ensure a high success rate and minimize the chance of false negatives.



- **Multiplexing:** For targeting multiple genes simultaneously or generating large genomic deletions, advanced cloning methods (like Golden Gate Assembly) allow for the delivery of up to **10, or even up to 30, different gRNAs** in a single vector, although efficiency may decrease with higher numbers.
- **Genome-wide Screens:** Pooled CRISPR screens use libraries containing tens of thousands of unique gRNAs to target every gene in the genome, with typically 3-6 different gRNAs per gene represented in the library pool.
- **Target Region Constraints:** For specific applications like CRISPR activ

On-Target Sites

- **Definition:** The specific, user-defined DNA sequence (typically 20 nucleotides long for Cas9) immediately upstream of a Protospacer Adjacent Motif (PAM, e.g., NGG for *S. pyogenes* Cas9) that the gRNA is designed to target.

- **Goal:** Maximize the binding and cleavage efficiency at this specific site to ensure the desired genetic modification (e.g., knockout or knock-in) occurs effectively.
- **Design Considerations:**
 - **Location:** For a gene knockout, targeting an early exon is often preferred to ensure a functional protein is not produced. For other applications (knock-in, activation/repression), the location might be more constrained, requiring a balance between location and sequence efficiency.
 - **Efficiency Score:** Bioinformatics tools provide an on-target activity score (usually 0-1), with higher scores indicating a greater likelihood of a successful edit.
 - **Chromatin Accessibility:** The target region should be in an accessible chromatin state for the Cas9 complex to bind efficiently.

Off-Target Sites

- **Definition:** Other locations in the genome that have enough sequence similarity (partial homology) to the gRNA target sequence (including the PAM) that the Cas9 complex can still bind and cleave, even with a few mismatches.
- **Concern:** Off-target activity can lead to unintended, non-specific genetic modifications, which can confound experimental results, cause unwanted phenotypes, or, in a therapeutic context, pose serious safety risks (e.g., disrupting a tumor-suppressor gene).
- **Design Considerations to Minimize Risk:**
 - **Specificity Score:** Design tools provide an off-target score, with higher scores typically indicating a lower potential for off-target activity (fewer potential off-target sites or fewer close matches).
 - **Sequence Uniqueness:** The chosen 20nt target sequence should be as unique as possible within the entire genome.

- **Mismatch Location:** Mismatches are better tolerated at the 5' end of the gRNA sequence (distal to the PAM) than at the 3' end (proximal to the PAM or "seed" region), so a good gRNA will avoid off-target sequences with perfect matches in the seed region.
- **gRNA Length/Modifications:** Using a slightly shorter gRNA (e.g., 17-18 nt) or incorporating specific chemical modifications can increase specificity.
- **Use of High-Fidelity Cas9:** Utilizing engineered high-fidelity Cas9 variants (like SpCas9-HF1 or HypaCas9) that are less tolerant of mismatches can significantly reduce off-target effects.
- **Validation:** Potential off-target sites predicted by in silico tools should be verified experimentally (e.g., via targeted deep sequencing or whole-genome sequencing) to confirm their activity or absence.

<https://www.ncbi.nlm.nih.gov/nuccore/EU899414.1>

Escherichia coli strain TW14359 flagellar biosynthesis protein FlhB (ECs2590) gene, complete cds

GenBank: EU899414.1

[FASTA](#) [Graphics](#)

Go to:

LOCUS	EU899414	1149 bp	DNA	linear	BCT 08-JUN-2009
DEFINITION	Escherichia coli strain TW14359 flagellar biosynthesis protein FlhB (ECs2590) gene, complete cds.				
ACCESSION	EU899414				
VERSION	EU899414.1				
KEYWORDS	.				
SOURCE	<i>Escherichia coli</i>				
ORGANISM	<i>Escherichia coli</i> Bacteria; Pseudomonadida; Pseudomonadota; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.				
REFERENCE	1 (bases 1 to 1149)				
AUTHORS	Leopold,S.R., Magrini,V., Holt,N.J., Shaikh,N., Mardis,E.R., Cagno,J., Ogura,Y., Iguchi,A., Hayashi,T., Mellmann,A., Karch,H., Besser,T.E., Sawyer,S.A., Whittam,T.S. and Tarr,P.I.				
TITLE	A precise reconstruction of the emergence and constrained radiations of <i>Escherichia coli</i> O157 portrayed by backbone concatenomic analysis				
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 106 (21), 8713-8718 (2009)				
PUBMED	19439656				
REFERENCE	2 (bases 1 to 1149)				
AUTHORS	Leopold,S.R., Magrini,V., Holt,N.J., Shaikh,N., Mardis,E.R., Cagno,J., Oguro,Y., Iguchi,A., Hayashi,T., Mellmann,A., Karch,H., Besser,T.E., Sawyer,S.A., Whittam,T.S. and Tarr,P.I.				

https://www.snapgene.com/plasmids/crispr_plasmids/pET28a_Cas9-Cys

pET28a Cas9-Cys


Bacterial plasmid for regulated expression of *S. pyogenes* Cas9 with a C-terminal cysteine.



Sequence Author: Kim Lab / Addgene #53261

[Open in SnapGene](#)

[Download SnapGene](#)

[Download Plasmid](#)





SEQUENCE MAP DESIGN PRIMER X LINEAR MAP DESCRIPTION METADATA RELEVANT ITEMS

Primer Pair Share Set from Selection

Design

Strand: Forward Reverse

Bases: 5' 3' **gtctttgataataactgtat** 3'

Primer must be at least 6 bp.

3' Location: 1 200

Overhang: 0 bp 0 bp

Cut Site: Enzyme

Use the dropdown above to look up restriction sites.

Verify

Check Secondary Structure at 37 °C

BASES 1149 START 200 END 219 LENGTH 20 GC 30.00% MELTING TEMP 44.3 °C

ASSEMBLY ▲ SPLIT WORKSPACE

SEQUENCE MAP LINEAR MAP DESCRIPTION DESIGN PRIMER X ...

Primer Pair Share Set from Selection

Design

Strand: Forward Reverse

Bases: 5' 3' **GCTAGCcatgc** 3'

Primer must be at least 6 bp.

3' Location: 206 1

Overhang: 11 0

Cut Site: NheI

Use the dropdown above to look up restriction sites.

Verify

Check Secondary Structure at 37 °C

BASES 1149 START 174 END 206 LENGTH 33 GC 54.55% MELTING TEMP 676 °C

ASSEMBLY ▲ SPLIT WORKSPACE

SEQUENCE MAP LINEAR MAP DESCRIPTION DESIGN PRIMER X ...

Primer Pair Share Set from Selection

Design

Strand: Forward Reverse

Bases: 5' 3' **GCTAGCcatgc** 3'

Primer must be at least 6 bp.

3' Location: 204 1

Overhang: 10 10

Cut Site: EcoRI

Use the dropdown above to look up restriction sites.

The specified primer pair does not result in a valid product. Make sure that the forward primer binds before the reverse primer if the sequence is linear.

Verify

Check Secondary Structure at 37 °C

BASES 1149 START 1121 END 1149 LENGTH 29 GC 37.93% MELTING TEMP 58.0 °C

ASSEMBLY ▲ SPLIT WORKSPACE

The screenshot shows the BioEdit software interface for primer design. The top window displays a sequence map for pET28a/Cas9-Cys, specifically for gene ECs2590 (flagellar biosynthesis protein FlhB). The bottom window is the 'DESIGN PRIMER' tab for EU899414. A yellow arrow points to the 'Save' button in the top right of the bottom window. Another yellow arrow points to the 'Primers' folder in the 'Save To' dropdown menu.

A leader sequence (atta/attc) in primer design is a small number of additional base pairs added to the 5' end of a primer to facilitate its function, most commonly to help a restriction enzyme cut more efficiently when cloning. This sequence of 3-6 nucleotides typically includes a restriction enzyme site and is positioned before the region of the primer that will bind to the DNA template.

The screenshot shows the BioEdit software interface. On the left, a sequence alignment is displayed with a green arrow indicating a primer binding site. The sequence is labeled "source Escherichia coli str. K-12 [ATCC 15459] FliB (Ec5290) gene, complete cds". The sequence itself is a DNA sequence:
catggata
gtactcatt
gtactcatt
gtactcatt
The right side of the screen shows a detailed view of a primer pair. A yellow box highlights the "Edit - Unlink" button. Another yellow box highlights the "Create PCR Product" button. The primer information is as follows:

Name	T _m
Forward Primer	primer-F 64.4°C
Reverse Primer	Primer-R 58.0°C

Product Size: 1020 bp
T_m Difference: -6.4°C

pET28a/Cas9-Cys

SEQUENCE MAP

NcoI

AAATAATTGTTAACCTTAAAGAAGGAGATACCATGGCAGCGCCATCATCATCATCACAGCAGCGGCCCTGG
TTTATTAACAAATTGAAATTCTCTCTATATGGTACCCGTCGCGTAGTAGTAGTAGTGCTGCCCCGACC

RBS 6xHis

2,770 2,780 2,790 2,800 2,810 2,820 2,830 2,840

NheI BmtI

BamHI

EcoRI

Eco53kI

SalI HincII

ACGGCGCGCGCGATACCGATCTGACTGACCACTCTGCTGTTACCGCGCTAGGGTAAAGCTCGAGGCAGCTGT

thro...ite T7 tag (gene 10 leader)


LINEAR MAP

pET28a/Cas9-Cys (9546 bp)

Enzyme	Cleavage Site (bp)
PacI	~9546
KpnI	~8300
Acc65I	~7800
BaeI	~7500
NotI	~7200
HindIII	~6800
IncI	~6500
Sall	~6200
IacI	~5800
Eco53kI	~5500
EcoRI	~5200
BstEII	~4800
Apal	~4500
BstI	~4200
BssHII	~3800
NotI	~3500
HincII	~3200
NdeI	~2800
HpaI	~2500
BstAPI	~2200
SbfI	~2000
Tth111I	~1800
PflMI	~1600
PsPOMI	~1400
XbaI	~1200
BstZ17I	~1000
PshAI	~800
MluI	~600
Sgai	~400
BsrGI	~3500
BstAPI	~3200
PmlI	~3000
HindIII	~2800
PsPOMI	~2500
PciI	~2200
KfII	~2000
AgeI	~1800
PsiI	~1600
BsmI	~1400
PciI	~1200
PaeR7I	~9500
TspMI	~9200
PspXI	~8800
XbaI	~8500
XhoI	~8200
SspI	~8000
IliI	~7800
AspI	~7500
NotI	~7200
PvuI	~6800
BspDI	~6500
NsiI	~6200
SmaI	~5800
PspI	~5500
BspI	~5200
NruI	~4800
BspI	~4500
NsiI	~4200
BspI	~3800
NsiI	~3500
BspI	~3200
NdeI	~2800
BspI	~2500
NsiI	~2200
BspI	~2000
NsiI	~1800
BspI	~1600
NsiI	~1400
BspI	~1200
NsiI	~1000

BASES 9546 INSERT 2905

ASSEMBLY ▲ SPLIT WORKSPACE



pET28a/Cas9-Cys EU899414 EU899414 [150-1149]

SEQUENCE MAP DIGEST X VIRTUAL DIGEST LINEAR MAP PLASMID DESCRIPTION METADATA RELEVANT ITEMS


Digest Save NEB


Enzymes Cuts Temp. 1.1 2.1 3.1 4/CS

EcoRI	1	37°C	25	100*	50	50*
NheI	1	—	Not available for this vendor			

Start End Length Left Cutter Left Overhang Right Cutter Right Overhang

2866	2904	39	NheI	5'	EcoRI	5'
2905	2865	9507	EcoRI	5'	NheI	5'





pET28a/Cas9-Cys EU899414

SEQUENCE MAP **DIGEST** **VIRTUAL DIGEST** **LINEAR MAP** **PLASMID** **DESCRIPTION**

SET FRAGMENT
Select an assembly fragment below.

Backbone → Insert →

Bases: 9546 **Start:** 2866 **End:** 2904 **Length:** 38

Contextual menu (Invert selection):

- Copy
- Copy special...
- Change case...
- Delete bases
- Invert selection**
- Create annotation
- Create primer...
- Create new part
- Create DNA sequence
- Create RNA sequence
- Create translation...
- Create AA sequence...
- Run Primer3
- Submit to NCBI BLAST
- Analyze as translation
- Optimize codons

TEMP: 71.6 °C

The screenshot shows the BioEdit software interface with three tabs at the top: pET28a/Cas9-Cys, EU899414, and EU899414 [150-1149] (highlighted in yellow). The main window displays a sequence map for the EU899414 [150-1149] region. A green line indicates the sequence, with a red arrow pointing to a restriction site. Enzyme sites MboII and BsaWI are marked with blue arrows. The sequence itself is shown below the map, with several restriction sites highlighted in red boxes. The bottom section provides a preview of the sequence and its orientation relative to the pET28a/Cas9-Cys vector.

The figure shows the Bionano Genomics Assembly interface for the pET28a/Cas9-Cys construct. The left panel displays a sequence map with restriction sites NdeI and BmtI, and insertion points at positions 2850 and 2930. The right panel shows a circular assembly diagram with various restriction sites and markers like ori, f1 ori, I7 terminator, and lacI promoter.

